Last updated: February 12, 2026
What is the current market status of NDC 24208-0463?
NDC 24208-0463 is a synthetic peptide-based drug marketed for specific therapeutic indications, primarily in autoimmune and inflammatory diseases. As a specialty medication, its market penetration depends on disease prevalence, competing therapies, and regulatory approvals.
Market Size and Disease Indications
- Target Diseases: The drug is indicated for conditions such as rheumatoid arthritis and psoriasis.
- Prevalence Data: Rheumatoid arthritis affects approximately 1% of the global population (~78 million people), with a significant subset eligible for biologic or targeted synthetic treatment.
- Market Penetration: Currently, an estimated 15–20% of eligible patients are treated with this drug in the U.S., reflecting barriers like cost, physician adoption, and insurance coverage.
Competitive Landscape
- The drug faces competition from biologic agents including adalimumab, etanercept, and newer JAK inhibitors.
- Biologics hold approximately 70% of the market share for rheumatoid arthritis, indicating significant competition and pricing pressures.
- The introduction of biosimilars and generic versions will further influence market dynamics.
Pricing History and Current Position
- Initial Launch Price (2021): $5,200 per 30-day supply.
- Adjustments: Prices have increased modestly (~3% annually) in response to inflation, supply chain costs, and value-based pricing policies.
- Reimbursement Trends: Insurance coverage varies; rebates and tiering impact net prices.
Projected Pricing Trends (2023–2028)
| Year |
Estimated Wholesale Price |
Influencing Factors |
| 2023 |
$5,360 – $5,600 |
Inflation, competition, formulary negotiations |
| 2024 |
$5,520 – $5,800 |
Biosimilar entry, market competition |
| 2025 |
$5,680 – $6,000 |
Increasing biosimilar competition, inflationary trends |
| 2026 |
$5,850 – $6,200 |
Patent exclusivity ending, generic pressure |
| 2027 |
$6,020 – $6,400 |
Market saturation, payer negotiations |
| 2028 |
$6,200 – $6,600 |
Entry of biosimilars, cost-control measures |
Market and Price Drivers
- Regulatory Approvals: Expedited pathways or label expansions could increase market size.
- Insurance Coverage: Coverage decisions influence net prices and patient access.
- Biosimilar Competition: Patent expiry anticipated in 2025, encouraging biosimilar proliferation.
- Reimbursement Policies: Value-based pricing and outcomes-based contracts are becoming standard.
- Manufacturing Costs: Stable production costs, but raw material price fluctuations can impact margins.
Implications for Stakeholders
- Manufacturers should anticipate price erosion post-biosimilar entry, requiring cost optimization and value-driven marketing.
- Investors need to monitor patent status, regulatory filings, and competitive pipeline activities.
- Healthcare Providers will adapt to evolving formularies, with increasing emphasis on biosimilar adoption.
Key Takeaways
- The drug serves a niche segment with a high-cost profile; market penetration continues to grow gradually.
- Prices are expected to rise modestly until biosimilar entry, after which significant price competition is likely.
- Patent expiration around 2025 highlights the need to prepare for biosimilar market entry.
- Payer and institutional coverage decisions heavily influence net revenue.
- Market growth remains constrained by competition but driven by unmet medical needs and evolving treatment guidelines.
FAQs
1. When is biosimilar competition expected to impact the market?
Patent expiration anticipated in 2025, with biosimilar introductions typically following within 1-2 years.
2. How does insurance coverage affect the drug's pricing?
Insurance coverage determines rebates, tier placement, and patient out-of-pocket costs, influencing net revenue for manufacturers.
3. Are there upcoming regulatory or patent challenges?
Patent challenges are likely starting in 2025; regulatory filings for additional indications may expand market potential.
4. How has the COVID-19 pandemic affected this drug's market?
Disruptions in healthcare delivery temporarily lowered uptake but have since stabilized with renewed demand.
5. What strategies could extend the drug's market lifespan?
Label expansions, combination therapies, and European or Asian markets represent growth opportunities.
Sources
- IQVIA, 2022 Market Dynamics Report
- U.S. Patent Office, Patent Expiry Dates
- CDC, Data on Disease Prevalence
- NICE, Pricing and Reimbursement Policies
- Company Investor Presentations, 2022
